Brainstorm Secures $1 Million Strategic Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: PRnewswire
- Financing Agreement: Brainstorm Cell Therapeutics announced a definitive agreement for a strategic private placement of $1 million, reflecting the company's operational momentum and the underlying value of its NurOwn® platform, which is expected to fund the upcoming ALS Phase 3b trial.
- Clinical Trial Preparation: The proceeds will support ongoing regulatory initiatives and prepayments for the upcoming ALS Phase 3b trial, indicating the company's strong commitment to advancing NurOwn® as an innovative treatment for ALS, potentially accelerating its market entry.
- Increased Market Confidence: CEO Chaim Lebovits stated that securing this financing at a premium to the current market is a powerful vote of confidence in Brainstorm's future trajectory, particularly in light of high-level engagements with regulatory authorities.
- Platform Potential: The NurOwn® technology platform utilizes autologous bone marrow-derived mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells, aiming to target disease pathways in neurodegenerative disorders, which could play a crucial role in ALS treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
